Rosenthal, Allison C.
Munoz, Javier L.
Villasboas, J. C.
Article History
Received: 14 March 2022
Accepted: 19 February 2023
First Online: 4 March 2023
Declarations
:
: Not applicable.
: Not applicable.
: Allison C. Rosenthal has nothing to disclose. Javier L. Munoz has served as a consultant for Abbvie/Pharmacyclics, ADC Therapeutics, Alexion, Bayer, BeiGene, Bristol Myers Squibb, Debiopharm, Epizyme, Inc, an Ipsen company, Fosunkite, Genmab, Gilead/Kite Pharma, Innovent, Janssen, Juno/Celgene, Karyopharm, Kyowa, Seagen, and Servier; has received research funding from Bayer, Celgene, Genentech, Gilead/Kite Pharma, Incyte, Janssen, Merck, Millennium, Pharmacyclics, Portola, and Seagen; has received honoraria from Curio, Kyowa, OncView, Physicians’ Education Resource, Seagen, and Targeted Oncology; and has served on speakers’ bureaus for Acrotech/Aurobindo, AstraZeneca, Bayer, BeiGene, Celgene/Bristol Myers Squibb, Genentech/Roche, Gilead/Kite Pharma, Kyowa, Pharmacyclics/Janssen, Seagen, and Verastem. J. C. Villasboas has received institutional funds from Epizyme, Inc, an Ipsen company, and acted as a principal investigator on a clinical trial for Epizyme, Inc, an Ipsen company.